These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 14563899

  • 1. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults.
    Garau J, Twynholm M, Garcia-Mendez E, Siquier B, Rivero A, 557 Clinical Study Group.
    J Antimicrob Chemother; 2003 Nov; 52(5):826-36. PubMed ID: 14563899
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
    Siquier B, Sánchez-Alvarez J, García-Mendez E, Sabriá M, Santos J, Pallarés R, Twynholm M, Dal-Ré R, 620 Clinical Study Group.
    J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    File TM, Garau J, Jacobs MR, Wynne B, Twynholm M, Berkowitz E.
    Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
    [Abstract] [Full Text] [Related]

  • 4. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults.
    File TM, Lode H, Kurz H, Kozak R, Xie H, Berkowitz E, 600 Study Group.
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3323-31. PubMed ID: 15328092
    [Abstract] [Full Text] [Related]

  • 5. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults.
    Petitpretz P, Chidiac C, Soriano F, Garau J, Stevenson K, Rouffiac E, 556 Clinical Study Group.
    Int J Antimicrob Agents; 2002 Aug; 20(2):119-29. PubMed ID: 12297361
    [Abstract] [Full Text] [Related]

  • 6. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
    File TM, Mandell LA, Tillotson G, Kostov K, Georgiev O.
    J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
    [Abstract] [Full Text] [Related]

  • 7. Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia.
    Lode H, Magyar P, Muir JF, Loos U, Kleutgens K, International Gatifloxacin Study Group.
    Clin Microbiol Infect; 2004 Jun; 10(6):512-20. PubMed ID: 15191378
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis.
    Sethi S, Breton J, Wynne B.
    Antimicrob Agents Chemother; 2005 Jan; 49(1):153-60. PubMed ID: 15616290
    [Abstract] [Full Text] [Related]

  • 9. Performance in practice: bacteriological efficacy in patients with drug-resistant S. pneumoniae.
    Garau J.
    Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():28-35. PubMed ID: 14759231
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetically enhanced amoxicillin/clavulanate (2,000/125 mg) in acute bacterial rhinosinusitis caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    Anon JB, Ferguson B, Twynholm M, Wynne B, Berkowitz E, Poole MD.
    Ear Nose Throat J; 2006 Aug; 85(8):500, 502, 504 passim. PubMed ID: 16999056
    [Abstract] [Full Text] [Related]

  • 11. Effect of opsonophagocytosis mediated by specific antibodies on the co-amoxiclav serum bactericidal activity against Streptococcus pneumoniae after administration of a single oral dose of pharmacokinetically enhanced 2000/125 mg co-amoxiclav to healthy volunteers.
    Alou L, Aguilar L, Sevillano D, Giménez MJ, Laguna B, Echeverría O, Carcas A, Lubomirov R, Casal J, Prieto J.
    J Antimicrob Chemother; 2005 May; 55(5):742-7. PubMed ID: 15761068
    [Abstract] [Full Text] [Related]

  • 12. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B.
    J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of twice-daily amoxycillin/clavulanate in lower respiratory tract infections.
    Balgos AA, Rodriguez-Gomez G, Nasnas R, Mahasur AA, Margono BP, Tinoco-Favila JC, Sansores-Martinez RH, Hassan M, Beppo O, Wongsa A, Cukier A, Vargas F.
    Int J Clin Pract; 1999 Jan; 53(5):325-30. PubMed ID: 10695094
    [Abstract] [Full Text] [Related]

  • 14. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis.
    Starakis I, Gogos CA, Bassaris H.
    Int J Antimicrob Agents; 2004 Feb; 23(2):129-37. PubMed ID: 15013037
    [Abstract] [Full Text] [Related]

  • 15. Randomized, double-blind study of the clinical efficacy of 3 days of azithromycin compared with co-amoxiclav for the treatment of acute otitis media.
    Dunne MW, Latiolais T, Lewis B, Pistorius B, Bottenfield G, Moore WH, Garrett A, Stewart TD, Aoki J, Spiegel C, Boettger D, Shemer A.
    J Antimicrob Chemother; 2003 Sep; 52(3):469-72. PubMed ID: 12888586
    [Abstract] [Full Text] [Related]

  • 16. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate.
    File TM, Jacobs MR, Poole MD, Wynne B, 546, 547, 548, 549, 550, 551, 556, 557 and 592 Clinical Study Groups.
    Int J Antimicrob Agents; 2002 Oct; 20(4):235-47. PubMed ID: 12385678
    [Abstract] [Full Text] [Related]

  • 17. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin.
    Léophonte P, File T, Feldman C.
    Respir Med; 2004 Aug; 98(8):708-20. PubMed ID: 15303634
    [Abstract] [Full Text] [Related]

  • 18. [Efficacy and safety of pristinamycin vs amoxicillin in community acquired pneumonia in adults].
    Trémolières F, Mayaud C, Mouton Y, Weber P, Dellatolas F, Caulin E.
    Pathol Biol (Paris); 2005 Aug; 53(8-9):503-10. PubMed ID: 16181747
    [Abstract] [Full Text] [Related]

  • 19. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies.
    Ortiz-Ruiz G, Vetter N, Isaacs R, Carides A, Woods GL, Friedland I.
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii59-66. PubMed ID: 15150184
    [Abstract] [Full Text] [Related]

  • 20. [Efficacy and tolerability of pristinamycin vs amoxicillin-clavulanic acid combination in the treatment of acute community-acquired pneumonia in hospitalized adults].
    Poirier R, Chardon H, Beraud A, Debieuvre D, Petitprez P, Montestruc F, Lilienthal F, Janus C.
    Rev Pneumol Clin; 1997 Jun; 53(6):325-31. PubMed ID: 9616826
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.